MPLT
MapLight Therapeutics, Inc.
Biotechnology
Market Cap$1.33B
5Y Perf.+10.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MPLT vs NRXP
Revenue, margins, valuation, and 5-year total return — side by side.
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$89M
5Y Perf.-57.4%
MPLT vs NRXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MPLT | NRXP |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.33B | $89M |
| Revenue (TTM) | $0.00 | $242K |
| Net Income (TTM) | $-103M | $-38M |
| Gross Margin | — | 59.5% |
| Operating Margin | — | -63.0% |
| Total Debt | $7M | $631K |
| Cash & Equiv. | $38M | $8M |
Quick Verdict: MPLT vs NRXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MPLT leads in 3 of 4 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
MPLT
MapLight Therapeutics, Inc.
The Long-Run Compounder
MPLT carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 62.6% 10Y total return vs NRXP's -96.7%
- Low D/E 5.7%, current ratio 7.20x
- current ratio 7.20x
Best for: long-term compounding and sleep-well-at-night
NRXP
NRx Pharmaceuticals, Inc.
The Growth Play
NRXP is the clearest fit if your priority is growth exposure.
- EPS growth 43.9%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | MPLT | 3.3% margin vs NRXP's -157.3% |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MPLT | +62.6% vs NRXP's +41.4% |
| Efficiency (ROA) | MPLT | -69.7% ROA vs NRXP's -489.9% |
MPLT vs NRXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
MPLT vs NRXP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMPLTLAGGINGNRXP
NRXPNRx Pharmaceuticals, …
0leads
MPLTMapLight Therapeutics…
3leads
6 Total Categories
CATEGORYLEADERvs NRXPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
MPLT1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
MPLT6/6
Risk & VolatilityBeta, volatility, and downside exposure
MPLT1/1
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
NRXP and MPLT operate at a comparable scale, with $242,000 and $0 in trailing revenue.
| Metric | MPLTMapLight Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $242,000 |
| EBITDAEarnings before interest/tax | -$108M | -$31M |
| Net IncomeAfter-tax profit | -$103M | -$38M |
| Free Cash FlowCash after capex | -$113M | -$12M |
| Gross MarginGross profit ÷ Revenue | — | +59.5% |
| Operating MarginEBIT ÷ Revenue | — | -63.0% |
| Net MarginNet income ÷ Revenue | — | -157.3% |
| FCF MarginFCF ÷ Revenue | — | -49.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | -80.0% |
Insufficient data to determine a leader in this category.
Valuation Metrics
MPLT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | MPLTMapLight Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Market CapShares × price | $1.3B | $89M |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $82M |
| Trailing P/EPrice ÷ TTM EPS | -15.66x | -2.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 72.54x |
| Price / BookPrice ÷ Book value/share | 10.53x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
MPLT leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
Evenly matched — MPLT and NRXP each lead in 2 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NRXP scores 5/9 vs MPLT's 4/9, reflecting solid financial health.
| Metric | MPLTMapLight Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| ROE (TTM)Return on equity | -2.1% | — |
| ROA (TTM)Return on assets | -69.7% | -4.9% |
| ROICReturn on invested capital | -153.7% | — |
| ROCEReturn on capital employed | -83.9% | — |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.06x | — |
| Net DebtTotal debt minus cash | -$32M | -$7M |
| Cash & Equiv.Liquid assets | $38M | $8M |
| Total DebtShort + long-term debt | $7M | $631,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -24.18x |
Evenly matched — MPLT and NRXP each lead in 2 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
MPLT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MPLT five years ago would be worth $16,263 today (with dividends reinvested), compared to $140 for NRXP. Over the past 12 months, MPLT leads with a +62.6% total return vs NRXP's +41.4%. The 3-year compound annual growth rate (CAGR) favors MPLT at 17.6% vs NRXP's -22.8% — a key indicator of consistent wealth creation.
| Metric | MPLTMapLight Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| YTD ReturnYear-to-date | +62.6% | +22.5% |
| 1-Year ReturnPast 12 months | +62.6% | +41.4% |
| 3-Year ReturnCumulative with dividends | +62.6% | -53.9% |
| 5-Year ReturnCumulative with dividends | +62.6% | -98.6% |
| 10-Year ReturnCumulative with dividends | +62.6% | -96.7% |
| CAGR (3Y)Annualised 3-year return | +17.6% | -22.8% |
MPLT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
MPLT leads this category, winning 1 of 1 comparable metric.
Risk & Volatility
MPLT currently trades 88.0% from its 52-week high vs NRXP's 83.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MPLTMapLight Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | — | 1.93x |
| 52-Week HighHighest price in past year | $33.28 | $3.84 |
| 52-Week LowLowest price in past year | $16.34 | $1.62 |
| % of 52W HighCurrent price vs 52-week peak | +88.0% | +83.6% |
| RSI (14)Momentum oscillator 0–100 | 59.2 | 57.4 |
| Avg Volume (50D)Average daily shares traded | 264K | 967K |
MPLT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MPLTMapLight Therapeu… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | $33.80 | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MPLT leads in 3 of 6 categories — strongest in Valuation Metrics and Total Returns. 1 category is tied.
Best OverallMapLight Therapeutics, Inc. (MPLT)Leads 3 of 6 categories
Loading custom metrics...
MPLT vs NRXP: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — MPLT or NRXP?
Over the past 5 years, MapLight Therapeutics, Inc.
(MPLT) delivered a total return of +62. 6%, compared to -98. 6% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: MPLT returned +59. 5% versus NRXP's -96. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is growing faster — MPLT or NRXP?
On earnings-per-share growth, the picture is similar: NRx Pharmaceuticals, Inc.
grew EPS 43. 9% year-over-year, compared to -39. 6% for MapLight Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
03Which has better profit margins — MPLT or NRXP?
MapLight Therapeutics, Inc.
(MPLT) is the more profitable company, earning 0. 0% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MPLT leads at 0. 0% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — NRXP leads at 59. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — MPLT or NRXP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is MPLT or NRXP better for a retirement portfolio?
For long-horizon retirement investors, MapLight Therapeutics, Inc.
(MPLT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MPLT: +59. 5%, NRXP: -96. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between MPLT and NRXP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.